Immunic Therapeutics’ Post

Our latest insight for Japan Exchange Group highlights the importance of platinum to a plethora of medical uses - from instrumentation to chemotherapy.

Rutherford, NJ, January 2, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, provides , updates on initial and long-term preclinical testing for the implantable Continuous Blood Glucose Monitor (CBGM). The Company announces the successful completion of their first preclinical study of the implantable CBGM. The study’s objective was to assess implant technique and device safety. In addition, a small sample size of sensors was used to determine device functionality. Although not intended to be an accuracy study, the sensor demonstrates a Mean Absolute Relative Difference (MARD) of 8.1% at Day 30 and 4.5% at Day 60. The study was completed with no significant adverse effects. “We are extremely pleased with these initial results demonstrating that the sensor is both safe and capable of a high level of accuracy” states Paul Goode, PhD, CEO of Glucotrack. “Because this study was performed using initial prototype devices, we expect to see similar results with improved prototypes that are manufactured using refined production techniques. So, we are very confident as we continue to advance our development program and as we share more information about our novel approach.” https://lnkd.in/gNJvFMUh #news #medical #latest #gluco #glucotrack #monitor #health #future

We are pleased to share that our team members Yijie Li, Nihal Engin Vrana, Baptiste Letellier, Philippe Lavalle, and Chloé Guilbaud-Chéreau published an insightful article titled "The Use of Supramolecular Systems in Biomedical Applications for Antimicrobial Properties, Biocompatibility, and Drug Delivery." This review covers the various supramolecular assemblies in different #biomedical applications, highlighting their potential to revolutionise healthcare. Click on the following link to read the full article: https://lnkd.in/dtuYsWnt https://lnkd.in/drPF6_rB #Antimicrobial #Biocompatibility #Innovation

The German Cabinet has just given the green light to draft laws that will revolutionize the healthcare system and unlock the potential of health data. 🏥💻 With a vision to enhance healthcare provision and research opportunities, Germany is taking a giant leap forward in its digitization efforts. These proposed laws include a groundbreaking “Fast-Track” system that will expedite clinical trials, allowing life-saving treatments and innovative solutions to reach patients faster than ever before. ⚡🔬 But that’s not all! Germany is also determined to optimize the use of health data, paving the way for advancements in medical research and pharmaceutical breakthroughs. 📊💉 By creating more favorable conditions for research and development, the government is making Germany an even more attractive destination for medical researchers and pharmaceutical companies. 🌐🔍 Get ready for a new era of healthcare innovation in Germany! 🚀 #healthcarerevolution #digitaltransformation #germany 🔗 Source: https://lnkd.in/eWs9J7kY Remember to like, comment, and share. Thank you!

THE GOAL of IWB/ ERFE: STIMULATING GROWTH IN AUSTRIA’S REGIONS   The main topics for funding in the period 2014-2020 was research and innovation, the shift to a low-carbon economy, and competitiveness. The funding was intended to strengthen growth and employment in all of Austria’s regions. In particular, the IGJ/ERDF programme provided funding to projects in the five areas in the 2014-2020 period (www.efre.gv.at.):   Priority 1: Enhancing regional competitiveness through research, technological development and innovation Priority 2: Enhancing the regional competitiveness of SMEs Priority 3: Supporting the shift towards a low-carbon economy in all sectors Priority 4: Sustainable urban development Priority 5: Integrated development of urban and surrounding areas and CLLD/LEADER   The EV-TT Transfer Center 2019 - 2022 was funded for enhancing regional competitiveness through research, technological development and innovation.   Therefore, after 3 months since EV-TT Project Closure it is our great pleasure to introduce Small New World Laboratories GmbH founded by Dr. Eva Rohde (Co-Founder, Medical Director & CEO) and Dr. Mario Gimona (Co-Founder, Scientific Director & CEO)   SNWlabs provides innovative solutions to improve tissue regeneration and to reduce fibrotic scar formation.   Visit our new Homepage https://snwlabs.eu/   Get in contact [email protected]   #snwlabs #efre #evttsalzburg #extracellularvesicles #exosomes #nanovesiculartherapy #atmps #biologicals #theralytics #frombenchtobedside #salzburg #research #science #gmp #manufacturing #pharma #innovation #regenerativemedicine #genetherapy #celltherapy #biologics #atmp

Your re-reading in preparation to #BioEurope 23 in #Munich: we had this in early August, study by Schuhmacher et al about how desperate Pharma is to incorporate external innovation. The former studies to the same topic in this article as well. They need you! You Biotech innovators: #biotechnology #innovation

🔬 Exciting News in Biomedical Innovation! 🚀 We proudly announce the successful patent grant for our groundbreaking invention titled "ANGIOGENIN AS A DIAGNOSTIC OR PROGNOSTIC BIOMARKER AND DRUG TARGET IN AGE-RELATED MACULAR DEGENERATION"! This breakthrough work identifies angiogenin as a pivotal biomarker with significant diagnostic and prognostic potential in Age-Related Macular Degeneration (AMD) and establishes it as a promising drug target, opening doors to novel therapeutic interventions. Kudos to our dedicated team whose unwavering commitment to advancing healthcare has led to this remarkable achievement. This patent marks a significant step in redefining the landscape of AMD diagnostics and treatment, underscoring our organization's commitment to making a positive impact on global health. Stay tuned for further updates on our journey towards transforming lives through biomedical innovation! #BiomedicalInnovation #AMD #HealthcareBreakthrough #MedicalResearch #Innovation #PatentGranted #ScientificAdvancement #MedicalScience 🌐👩🔬👨🔬

Going into the Holiday Weekend feeling excited… With 25+ clinical studies, 7 U.S. patents and counting, and over 1 MILLION patients treated, BENEV has helped enhance the recovery process worldwide by harnessing the power of exosomes. And as the world’s LEADING brand, we are dedicated to research and innovation to ensure we deliver the best exosomes on the market. New science is coming, and we can’t wait to see what is on the horizon for BENEV Exosomes! Stay tuned… #benevexosomes #exosometechnology #exosometreatment *Disclaimer: BENEV Exosome Regenerative Complexes are not drug products. They are not intended to prevent, treat, or cure diseases or medical conditions. They are not intended to be injected or delivered intravenously.

#Health | 𝗖𝗮𝘂𝘀𝗲 𝗼𝗳 𝗖𝗹𝗼𝗴𝗴𝗲𝗱 𝗛𝘆𝗽𝗼𝗱𝗲𝗿𝗺𝗶𝗰 𝗡𝗲𝗲𝗱𝗹𝗲𝘀 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝗲𝗱 | The team of researchers led by Dr. Vladimir Novak has put forward new techniques to understand and prevent blockages in prefilled syringes. This study was also made possible by the PSI Paul Scherrer Institut and ANAXAM - Technology transfer center for advanced manufacturing, in collaboration with MSD, Dr. Margie Olbinado, Dr. David Mannes, and Dr. Christian Grünzweig. The research took an in-depth look at needles using neutron and synchrotron imaging. They deciphered potential blockage causes and set conditions to prevent future occurrences. This work is crucial considering the possible serious implications of blocked syringes for patients - impeded medication entry or insufficient dosages. The insights this study offers can enhance pre-filled syringes' safety and reliability for pharmaceutical companies and healthcare professionals. 👉 Learn more >> https://lnkd.in/gDXky7XB 👉 Original publication >> https://lnkd.in/geZU6q8b 🇨🇭 Follow #ScienceSwitzerland for the latest news and emerging trends on Swiss science, technology, education, and innovation >> www.swissinnovation.org Follow us >> Science-Switzerland #Science | #Education | #Research | #Innovation

Traditionally, drug development and clinical trials have primarily focused on male subjects in early clinical trials. This male-centric approach has resulted in a significant gap in our understanding of how drugs interact with female physiology, leading to potential disparities in drug efficacy and safety for women. How to improve this in your development? Our non-clinical experts Arthur Noach and André Wolterbeek share their insights! https://lnkd.in/e5f2G_5s